Drug Trial Radar · NCT06733402
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Jun 20, 2024
Primary completion
Jun 20, 2024
Study completion Nov 9, 2024
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
Trifarotene Cream 0.005%Drug
A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUGDrug
A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCTDrug
A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
PlaceboDrug
A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate the therapeutic equivalence, efficacy and safety of the Investigational ProductTime frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taro Pharmaceuticals USA Inc.
Hawthorne, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.